H.C. Wainwright lowered the firm’s price target on Curis (CRIS) to $20 from $26 and keeps a Buy rating on the shares. The firm cites dilution from this week’s registered direct offering for the target cut. Additional data from the TakeAim lymphoma study is expected in December and in Q1 of 2025, the analyst tells investors in a research note.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRIS: